Mostrar el registro sencillo del ítem

Caracterización de la aloinmunización eritrocitaria en el Hospital Universitario del Valle entre 2011 y 2013

dc.contributor.authorPérez Carrillo, José Arnulfospa
dc.contributor.authorCortés Buelvas, Armandospa
dc.date.accessioned2020-10-27T14:20:08Z
dc.date.available2020-10-27T14:20:08Z
dc.date.issued2014-11-04
dc.identifier.issn2382-4603
dc.identifier.issn0123-7047
dc.identifier.urihttp://hdl.handle.net/20.500.12749/10137
dc.description.abstractLas necesidades nacionales de sangre están parcialmente cubiertas. El uso de la sangre implica la detección e identificación de anticuerpos inesperados en los receptores de componentes eritrocitarios. Objetivo: Caracterizar demográfica y clÍnicamente los casos de aloinmunización eritrocitaria en el servicio transfusional del Hospital Universitario del Valle (HUV), Cali, Valle del Cauca, Colombia entre 2011 y 2013. MetodologÍa: Se diseñó un estudio de corte transversal con los casos de aloinmunización eritrocitaria transfundidos por el servicio transfusional del HUV entre el 1 de agosto del 2011 hasta el 31 de julio del 2013. Los casos se incluyeron a través de un muestreo con asignación al azar sistemático. Para ingreso de datos y análisis se empleó el programa Epi-Info para Windows®. El estudio contó con aprobación del Comité de ética. Resultados: Se incluyeron 80 casos de los cuales el 53.8% eran de género femenino y el 46.2% masculino. Además, el 65% correspondÍa a raza mestiza hispana y el 35% a afrodescendientes. El 22.5% tenÍa antecedentes de enfermedades hematopoyéticas y el 45% estaban hospitalizados por diagnósticos incluidos en esta categorÍa del CIE-10. El 79% de las mujeres tenÍan historia obstétrica. El 18.75% fueron transfundidos previamente. El 36% de los casos contaba con un fenotipo CceeK. El 31.25% tenÍan aloanticuerpo Anti-E, seguido por Anti-K con el 21.25%. Conclusiones: El principal aloanticuerpo identificado fue Anti-E seguido de Anti-K. Asimismo existe un grupo importante de pacientes en los cuales no se pudo identificar el aloanticuerpo asociado, debido principalmente a mezcla de anticuerpos. Además, la mayorÍa de los casos corresponde a adultos jóvenes y adultos. En relación con las caracterÍsticas clÍnicas de la muestra se observó una representación discreta de las hemoglobinopatÍas congénitas y la mayorÍa no fueron politransfundidos previamente. [Pérez JA, Cortés A. Caracterización de la aloinmunizacióneEritrocitaria en el Hospital Universitario del Valle entre 2011 y 2013. MedUNAB 2014; 17(2):66-80]spa
dc.format.mimetypeapplication/pdfspa
dc.format.mimetypeApplication/vnd.openxmlformats-officedocument.wordprocessingml.documentspa
dc.format.mimetypeApplication/mswordspa
dc.format.mimetypeApplication/mswordspa
dc.format.mimetypeApplication/vnd.openxmlformats-officedocument.wordprocessingml.documentspa
dc.language.isospaspa
dc.publisherUniversidad Autónoma de Bucaramanga UNAB
dc.relationhttps://revistas.unab.edu.co/index.php/medunab/article/view/2086/1975
dc.relationHttps://revistas.unab.edu.co/index.php/medunab/article/view/2086/2707
dc.relationHttps://revistas.unab.edu.co/index.php/medunab/article/view/2086/2708
dc.relationHttps://revistas.unab.edu.co/index.php/medunab/article/view/2086/2709
dc.relationHttps://revistas.unab.edu.co/index.php/medunab/article/view/2086/2717
dc.relation.urihttps://revistas.unab.edu.co/index.php/medunab/article/view/2086
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.sourceMedUNAB; Vol. 17 Núm. 2 (2014): Agosto - Noviembre de 2014: Mieloma múltiple, Aloinmunización eritrocitaria, Riesgo cardiovascular; 66-80
dc.titleCaracterización de la aloinmunización eritrocitaria en el Hospital Universitario del Valle entre 2011 y 2013
dc.title.translatedCharacterization of Red Blood Cells Alloimmunization at Hospital Universitario del Valle between 2011 and 2013eng
dc.title.translatedCaracterização de aloimunização eritrocitária no Hospital Universitário do Valle no período de 2011 a 2013port
dc.publisher.facultyFacultad Ciencias de la Salud
dc.publisher.programPregrado Medicina
dc.type.driverinfo:eu-repo/semantics/article
dc.type.localArtículospa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501
dc.subject.keywordsRh Isoimmunizationeng
dc.subject.keywordsIsoantigenseng
dc.subject.keywordsBlood Group Antigenseng
dc.subject.keywordsHemoglobinopathieseng
dc.subject.keywordsErythrocyte Transfusioneng
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga UNABspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.relation.referencesMinisterio de la Protección Social. Política nacional en sangre.[Internet].BogotáD.C.:Ministeriodela Protección Social; 2007 [actualizado 6 Ago 2007; Acceso 31 Ago 2014]
dc.relation.referencesEngelfriet CP, Reesink HW, Fontão-Wendel R, Lazar A, et al. Prevention and diagnosis of delayed hemolytic transfusion reactions. Vox Sang [Internet]. 2006 [Acceso 31May2014];91(4):353–368.Disponibleen: http://dx.doi.org/10.1111/j.1423-0410.2006.00812_1
dc.relation.referencesCortesAD.PrevencióndelaAloinmunizacióna AntígenosEritrocitarios.RevistaArgentinade Transfusión. 2012; 38(2): 155- 160.
dc.relation.referencesVichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990; 322(23): 1617-1621
dc.relation.referencesRosse WF, Gallagher D, Kinney TR, Castro O. The cooperative study of sickle cell disease. Transfusion and alloimmunization in sickle cell disease. Blood. 1990; 76:1431-147
dc.relation.referencesPineda AA, Vamvakas EC, Gorden ID, Winter JJ, Moore SB. Trends in the incidence of delayed hemolytic an delayed serologic transfusion reactions. Transfusion. 1999; 39(10): 1097-1103
dc.relation.referencesPineda AA, Taswell HF, Brzica SM. Transfusion reaction. Animmunologichazardofbloodtransfusion. Transfusion. 1978; 18(1): 1-7
dc.relation.referencesAbou-Elella AA, Camarillo TA, Allen MB, Barclay S, Pierce JA, Holland HK, et al. Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Transfusion. 1995; 35(11): 931-935
dc.relation.referencesAmeen R, Al Shemmari S, Al-Bashir A. Red blood cell alloimmunization among sickle cell Kuwaiti Arab patients who received red blood cell transfusion. Transfusion. 2009; 49(8): 1649 –1654
dc.relation.referencesTormey CA, Fisk J, Stack G: Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion. 2008; 48(10): 2069 – 2076
dc.relation.referencesDeLaRubiaJ,ArriagaF,AndreuR,SanzG,et al.Developmentofnon-ABORBCalloantibodiesin patients undergoing allogeneic HPCtransplantation. ¿Is ABOincompatibility a predisposing factor?. Transfusion. 2001; 41(1): 106-110
dc.relation.referencesHiggins JM, Sloan SR. Stochastic modeling of human RBCalloimmunization: evidence for a distinct population of immunologic responders. Blood. 2008; 112(6): 2546 – 2553
dc.relation.referencesChouST,LiemRI,ThompsonAA.Challengesof alloimmunization in patients with hemoglobinopathies. Br J Haematol. 2012; 159(4): 394-404.
dc.relation.referencesDavies SC, McWilliam AC, Hewitt PE, Devenish A, Brozovic M. Red cell alloimmunization in sickle cell disease. Br J Haematol. 1986; 63: 241–245
dc.relation.referencesNatukunda B, Schonewille H, Ndugwa C, Brand A. Red blood cell alloimmunization in sickle cell disease patients in Uganda. Transfusion. 2010; 50(1): 20-25
dc.relation.referencesAygun B, Padmanabhan S, Paley C, Chandrasekaran V. ClinicalsignificanceofRBCalloantibodiesand autoantibodiesinsicklecellpatientswhoreceived transfusions. Transfusion. 2002; 42(1): 37-43
dc.relation.referencesMotaM,BleyC,AravechiaMG,HamerschlakN, Sakashita A, Kutner JM, et al. Autoantibody formation afteralloimmunizationinducingbystanderimmune hemolysis. Immunohematology. 2009; 25(1): 9-12
dc.relation.referencesTormeyCA,StackGS.Thepersistenceand evanescenceofbloodgroupalloantibodiesinmen. Transfusion. 2009; 49(3): 505 – 512
dc.relation.referencesBowman JM. Treatment options for the fetus with alloim-mune hemolytic disease. Transfus Med. 1990; 4: 191-207
dc.relation.referencesVamvakas EC, Blajchman MA. Blood Still Kills: Six strategiestofurtherreduceallogeneicblood transfusion-related mortality. Transfus Med Rev. 2010; 24 (2): 77 – 124
dc.relation.referencesKennaDS,NagarajaHN,O'ShaughnessyR. Management of pregnancies complicated by anti-Kell isoimmunization. Obstet Gynecol. 1999; 93(5): 667–673
dc.relation.referencesClarke CA, Mollison PL. Deaths from Rh haemolytic disease of fetus and newborn, 1977-1987. J R Coll Phys. 1989; 23:181–184
dc.relation.referencesFluit CR, Kunst VA, Drenthe-Schonk AM. Incidence of redcellantibodiesaftermultiplebloodtransfusion. Transfusion. 1990; 30(6): 532-535
dc.relation.referencesKoelewijn JM. Risk factors for RhD immunization despite antenatal and postnatal anti-D prophylaxis. BJGO. 2009; 116: 655-64
dc.relation.referencesHoeltge GA, Domen RE, Rybicki LA, Schaffer PA. Multipleredcelltransfusionsandalloimmunization. Experience with 6996 antibodies detected in a total of 159.262 patients from 1985 to 1993. Arch Pathol Lab Med. 1995; 119(1): 42-45
dc.relation.referencesHeddle NM, Soutar RL, O'Hoski PL, Singer J, McBride JA, Ali MA, Kelton JG. Aprospective study to determine the frequency and clinical significance of alloimmuniza-tion post-transfusion. Br J Haematol. 1995; 91:1000-1005
dc.relation.referencesThompson AA. Ideal donors, imperfect results in sickle cell disease. Blood. 2013; 122(6): 858-859
dc.relation.referencesPita S. Determinación del tamaño muestral. Cad Aten Prim. 1996; 3: 138 - 144
dc.relation.referencesLancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Prac. 2002; 10(2): 307–312
dc.relation.referencesWorldHealthOrganization.Internationalstatistical classification of diseases and health related problems ICD-10. 2 ed. Geneva, Switzerland: WHOpublications; 2004
dc.relation.referencesNatukunda B, Schonewille H, van de Watering L, Brand A.Prevalenceandspecificitiesofredbloodcell alloantibodies in transfused Ugandans with different diseases. Vox Sang [Internet]. 2010 [Acceso 31 may 2014]; 98(2): 167-171. Disponible en: http://doi:10.1111/ j.1423-0410.2009.01241
dc.relation.referencesZimring JC, Welniak L, Semple JW, Ness PM, Slichter SJ,SpitalnikSL;NHLBIAlloimmunizationWorking Group.Currentproblemsandfuturedirectionsof transfusion – induced alloimmunization: summary of an NHLBIworkinggroup.Transfusion[Internet]. 2011[Acceso 31 may 2014]; 51(5): 435 - 441. Disponible en: http://doi:10.1111/j.1537-2995.2010.03024
dc.relation.referencesUrreaF,etal.Cuantossomos,Comovamos. Diagnóstico Sociodemográfico de Cali y 10 municipios del pacífico nariñense. 1ª Edición. Editora Afroamérica XXI. Santiago de Cali, Valle de Cauca, Colombia
dc.relation.referencesNatukunda B, Brand A, Schonewille H. Red Blood cell alloimmunization from an African perspective. Curr Opin Hemat 2010; 17: 565 – 570. Disponible en http://doi: 10.1097/MOH.0b013e32833ec54b
dc.relation.referencesSaiedDA,KaddahAM,EldinRM,MohasebSS. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent egyptian thalassemic patients. J Pediatr Hematol Oncol 2011; 33:409–414. Disponible en: http://doi: 10.1097/MPH.0b013e3182208154
dc.relation.referencesDueñasVH,CortésAD,RovettoP.Embarazoy transfusiónysuasociaciónconaloanticuerpos inesperadosdesignificanciaclínicaconantígenos eritrocitarios. Colombia Med 1999; 30: 26-31
dc.contributor.cvlacPérez Carrillo, José Arnulfo [0001128493]
dc.contributor.cvlacCortés Buelvas, Armando [0001125273]
dc.contributor.googlescholarPérez Carrillo, José Arnulfo [m0Hvm0EAAAAJ&hl=es&oi=ao]
dc.contributor.orcidPérez Carrillo, José Arnulfo [0000-0003-0636-4959]
dc.subject.lembCiencias de la salud
dc.subject.lembMedicina
dc.subject.lembCiencias medicas
dc.identifier.repourlrepourl:https://repository.unab.edu.co
dc.description.abstractenglishThe national blood needs are partially covered. The use of blood involves the detection and identification of unexpected red cell receptor antibodies. Objective: The objective was to characterize demographically and clinically cases of erythrocyte alloimmunization at Transfusion Service of the University Hospital of the Valle (Cali, Valle del Cauca) between 2011 and 2013. Methodology: A cross-sectional design of cases of red cell alloimmunization transfused between august 1th 2011 until july 31th 2013. The cases were included through a systematic random sampling. Epi-Info for Windows® was used for the development of the instrument, data entry and statistical analysis. The research was approved by the Ethics Committee on Research of the Universidad Autónoma de Bucaramanga and HUV. Results: Out of the eighty cases, 53.8 % were female and 46.2% were male. 65% were Hispanic and 35% African-American. 22.5% had a history of hematopoietic diseases and 45% were hospitalized for diagnoses included in this category of ICD-10. 79% of women had obstetric history. 18.75% were transfused previously. 36% of the cases had a CceeK- phenotype. 31.25% had alloantibody Anti-E followed by Anti-K 21.25%. Conclusions: The major alloantibody identified was Anti-E followed by Anti-K. Additionally, the associated alloantibody could not be identified in a large group mainly due to antibody mixture. Also, most cases correspond to young adults and adults. In the clinical characteristics of the sample a discrete representation of congenital hemoglobinopathies was observed and most were not previously polytransfused.[Pérez JA, Cortés A. Characterization of Red Blood Cells Alloimmunization at Hospital Universitario del Valle between 2011 and 2013. MedUNAB 2014; 17(2):66-80]eng
dc.subject.proposalRh isoimmunization
dc.subject.proposalIsoantigens
dc.subject.proposalBlood group antigens
dc.subject.proposalHemoglobinopathies
dc.subject.proposalErythrocyte transfusion
dc.identifier.doi10.29375/01237047.2086
dc.type.redcolhttp://purl.org/redcol/resource_type/ART
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*


Ficheros en el ítem

Thumbnail
Nombre:
2014_Caracterización_de_la_alo ...
Tamaño:
266.5Kb
Formato:
PDF
Descripción:
Articulo
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 2.5 Colombia
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 2.5 Colombia